Swedish Orphan Biovitrum appoints Anders Edvell as new Head of Sales and Marketing

Stockholm, Sweden November 3, 2010 - Swedish Orphan Biovitrum (STO: SOBI) today announced that Anders Edvell has been appointed new VP of Marketing & Sales in Sobi.  He will be the successor of Kennet Rooth, as he leaves his position January 10, 2011 for personal reasons. Anders Edvell is an MD and PhD in medicine, and has an MBA degree from the Stockholm School of Economics. Anders has held several positions in the pharmaceutical industry, nationally as well as internationally. He joined Swedish Orphan International in August 2006 as Country Manager for Sweden and has, since March 2010, acted as Northern European Regional Director at Sobi. Furthermore, he has also from time to time been significantly involved the business development of Swedish Orphan International. "I am personally looking forward to work with Anders and to continue to build the successful Sobi business, initiated by Kennet Rooth. While it was with my deepest regret that I accepted Kennet's resignation, I fully appreciated his personal reasons for retiring. I am pleased that he will continue to support Sobi, on a part time consultancy basis, after formally leaving Sobi in January 2011. This will give us a good support and continuity going forward," says Sobi's CEO Martin Nicklasson. About Swedish Orphan Biovitrum Swedish Orphan Biovitrum is a Swedish based niche specialty pharmaceutical company with an international market presence. The company is focused on providing and developing specialist pharmaceuticals for rare disease patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipe-line. Our focus areas are: hemophilia, inflammation/autoimmune diseases, fat malabsorption, cancer and inherited metabolic disorders. Swedish Orphan Biovitrum had pro-forma revenues 2009e of about 2 BSEK and approximately 500 employees. The head office is located in Sweden and the share (STO: SOBI) is listed on NASDAQ OMX Stockholm. For more information please visitwww.sobi.com. For more information please contact: Swedish Orphan Biovitrum AB (publ): Erik Kinnman, VP Investor Relations Phone:+46 73 422 15 40 E-mailerik.kinnman@sobi.com Martin Nicklasson, CEO Phone: +46 8 697 20 00 Swedish Orphan Biovitrum may be required to disclose the information provided herein pursuant to the Swedish Securities Markets Act. The information was provided for public release on November 3, 2010 at 3 p.m. CET. [HUG#1458549] Press release in PDF format: http://hugin.info/134557/R/1458549/398033.pdf This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE